Palumbo Wealth Management LLC lifted its holdings in shares of Assertio Holdings, Inc. (NASDAQ:ASRT – Free Report) by 9.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 185,961 shares of the company’s stock after acquiring an additional 15,863 shares during the quarter. Palumbo Wealth Management LLC’s holdings in Assertio were worth $219,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in ASRT. Point72 DIFC Ltd acquired a new position in Assertio in the 2nd quarter worth $40,000. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in Assertio by 304.0% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 50,500 shares of the company’s stock worth $60,000 after buying an additional 38,000 shares in the last quarter. Marshall Wace LLP acquired a new position in Assertio in the 2nd quarter worth $70,000. Los Angeles Capital Management LLC acquired a new position in Assertio in the 2nd quarter worth $77,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Assertio in the 2nd quarter worth $149,000. Institutional investors and hedge funds own 48.96% of the company’s stock.
Assertio Stock Performance
Shares of NASDAQ:ASRT traded down $0.02 during trading on Thursday, reaching $1.03. 50,667 shares of the company’s stock traded hands, compared to its average volume of 916,588. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.93 and a quick ratio of 1.51. Assertio Holdings, Inc. has a 12 month low of $0.73 and a 12 month high of $2.37. The company has a 50 day moving average of $1.18 and a 200-day moving average of $1.17. The stock has a market capitalization of $98.20 million, a P/E ratio of -0.27 and a beta of 0.79.
Analysts Set New Price Targets
ASRT has been the topic of a number of recent analyst reports. Maxim Group initiated coverage on shares of Assertio in a report on Friday, July 26th. They issued a “buy” rating and a $3.00 price objective on the stock. HC Wainwright initiated coverage on shares of Assertio in a research report on Wednesday, July 3rd. They issued a “buy” rating and a $4.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $3.44.
View Our Latest Stock Report on ASRT
About Assertio
Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
Featured Articles
- Five stocks we like better than Assertio
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Why is the Ex-Dividend Date Significant to Investors?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Most Volatile Stocks, What Investors Need to Know
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Want to see what other hedge funds are holding ASRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assertio Holdings, Inc. (NASDAQ:ASRT – Free Report).
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.